Quantitative analysis and parametric imaging of 18F-labeled monomeric and dimeric RGD peptides using compartment model

Molecular Imaging and Biology

Volumn 14, Issue 6, 2012, Pages 743-752

  Guo, Ning ^a,b,c   Lang, Lixin ^c   Gao, Haokao ^c   Niu, Gang ^c   Kiesewetter, Dale O ^c   Xie, Qingguo ^a,b   Chen, Xiaoyuan ^c  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

Integrin; Kinetic modeling; Positron emission tomography; Quantitative analysis; RGD peptide

Indexed keywords

FLUORINE FPPRGD2 F 18; FLUORINE FPRGD F 18; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; COMPARTMENT MODEL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BINDING; DRUG STRUCTURE; DRUG UPTAKE; FEMALE; MOLECULAR IMAGING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; IMAGING, THREE-DIMENSIONAL; KINETICS; MICE; MICE, NUDE; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN MULTIMERIZATION; TIME FACTORS; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84870470028     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-012-0541-7     Document Type: Article

References (35)

1. Beer AJ, Schwaiger M (2008) Imaging of integrin alphavbeta3 expression. Cancer Metastasis Rev 27:631-644
2. Kimura RH, Cheng Z, Gambhir SS et al (2009) Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects. Cancer Res 69:2435-2442
3. Hood JD, Cheresh DA (2002) Role of integrins in cell invasion and migration. Nat Rev Cancer 2:91-100
4. Haubner R, Wester HJ, Weber WA et al (2001) Noninvasive imaging of αvβ3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 61:1781-1785
5. Niu G, Chen X (2011) Why integrin as a primary target for imaging and therapy. Theranostics 1:30-47
6. Beer AJ, Kessler H, Wester HJ et al (2011) PET imaging of integrin αvβ3 expression. Theranostics 1:48-57
7. Chen X (2006) Multimodality imaging of tumor integrin αvβ3 expression. Mini Rev Med Chem 6:227-234
8. Dumont RA, Deininger F, Haubner R et al (2011) Novel 64Cu-and 68Ga-labeled RGD conjugates show improved PET imaging of αvβ3 integrin expression and facile radiosynthesis. J Nucl Med 52:1276-1284
9. Mittra ES, Goris ML, Iagaru AH et al (2011) Pilot pharmacokinetic and dosimetric studies of 18F-FPPRGD2: a PET radiopharmaceutical agent for imaging αvβ3 integrin levels. Radiology 260:182-191
10. Chin FT, Shen B, Liu S et al (2012) First experience with clinical-grade [18F]FPP(RGD)2: an automated multi-step radiosynthesis for clinical PET studies. Mol Imaging Biol 14:88-95.
11. Battle MR, Goggi JL, Allen L et al (2011) Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled αvβ3-integrin and αvβ5-integrin imaging agent. J Nucl Med 52:424-430
12. Liu S (2009) Radiolabeled cyclic RGD peptides as integrin αvβ3-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug Chem 20:2199-2213
13. Schottelius M, Laufer B, Kessler H et al (2009) Ligands for mapping αvβ3-integrin expression in vivo. Acc Chem Res 42:969-980
14. Cai W, Chen X (2008) Preparation of peptide-conjugated quantum dots for tumor vasculature-targeted imaging. Nat Protoc 3:89-96
15. Jeong JM, Hong MK, Chang YS et al (2008) Preparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4, 7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice. J Nucl Med 49:830-836
16. Wu Y, Zhang X, Xiong Z et al (2005) microPET imaging of glioma integrin αvβ3 expression using 64Cu-labeled tetrameric RGD peptide. J Nucl Med 46:1707-1718
17. Sun X, Yan Y, Liu S et al (2011) 18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy. J Nucl Med 52:140-146
18. Liu S, Liu Z, Chen K et al (2010) 18F-labeled galacto and PEGylated RGD dimers for PET imaging of αvβ3 integrin expression. Mol Imaging Biol 12:530-538
19. Zhang X, Xiong Z, Wu Y et al (2006) Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J NuclMed 47:113-121
20. Liu Z, Liu S, Wang F et al (2009) Noninvasive imaging of tumor integrin expression using 18F-labeled RGD dimer peptide with PEG4 linkers. Eur J Nucl Med Mol Imaging 36:1296-1307
21. Shoghi KI (2009) Quantitative small animal PET. Q J Nucl Med Mol Imaging 53:365-373
22. Hong YT, Beech JS, Smith R et al (2011) Parametric mapping of [18F] fluoromisonidazole positron emission tomography using basis functions. J Cereb Blood Flow Metab 31:648-657
23. Beer AJ, Haubner R, Goebel M et al (2005) Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med 46:1333-1341
24. Ferl GZ, Dumont RA, Hildebrandt IJ et al (2009) Derivation of a compartmental model for quantifying 64Cu-DOTA-RGD kinetics in tumor-bearing mice. J Nucl Med 50:250-258
25. Yang M, Gao H, Zhou Y et al (2011) 18F-labeled GRPR agonists and antagonists: a comparative study in prostate cancer imaging. Theranostics 1:220-229
26. Quan Q, Yang M, Gao H et al (2011) Imaging tumor endothelial marker 8 using an 18F-labeled peptide. Eur J Nucl Med Mol Imaging 38:1806-1815
27. Phelps ME, Huang SC, Hoffman EJ et al (1979) Tomographic measurement of local cerebral glucose metabolic rate in humans with 18F-2-fluoro-2-deoxy-D- glucose: validation of method. Ann Neurol 6:371-388
28. Akaike H (1974) A new look at the statistical model identification. IEEE Trans Automat Contr AC:716-723
29. Watabe H, Ikoma Y, Kimura Y et al (2006) PET kinetic analysis -compartmental model. Ann Nucl Med 20:583-588
30. Innis RB, Cunningham VJ, Delforge J et al (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533-1539
31. Li ZB, Chen K, Chen X (2008) 68Ga-labeled multimeric RGD peptides for microPET imaging of integrin αvβ3 expression. Eur J Nucl Med Mol Imaging 35:1100-1108
32. Tomasi G, Turkheimer F, Aboagye E (2011) Importance of quantification for the analysis of PET data in oncology: review of current methods and trends for the future. Mol Imaging Biol. doi:10.1007/s11307-011-0514-2
33. Li ZB, Cai W, Cao Q et al (2007) 64Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor αvβ3 integrin expression. J Nucl Med 48:1162-1171
34. Chen X, Tohme M, Park R et al (2004) Micro-PET imaging of αvβ3-integrin expression with 18F-labeled dimeric RGD peptide. Mol Imaging 3:96-104
35. Tomasi G, Kenny L, Mauri F et al (2011) Quantification of receptorligand binding with [18F]fluciclatide in metastatic breast cancer patients. Eur J Nucl Med Mol Imaging 38:2186-2197